CClinicalTrials.gg
CompletedNCT06408545Updated Apr 23, 2025

Acceptance and Commitment Therapy for Problematic Chemsex

An interventional study of Acceptance and Commitment Therapy (ACT) in Hypersexuality, Compulsive Sexual Behavior and Sexualized Drug Use (Chemsex), sponsored by Universidad Europea de Madrid. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by Universidad Europea de Madrid · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Investigation of the efficacy of Acceptance and Commitment Therapy (ACT) for the psychological treatment of problematic chemsex. As a pilot study, the intervention will be tested in a small group.

Read the detailed description

After being informed about the study, all patients giving written informed consent will be assessed to determine eligibility for study entry.

Patients who meet eligibility requirements will receive psychological intervention consisting in an 8-session individual on line-delivered ACT-based treatment.

The participants will be assessed through self-report instruments before and after treatment and at 3 months follow-up.

The pilot study will not include a control group.

02

Conditions studied

  • Hypersexuality
  • Compulsive Sexual Behavior
  • Sexualized Drug Use (Chemsex)

Keywords

  • Sexuality
  • Risky sexual behavior
03

In context

Lead sponsor

Universidad Europea de Madrid is the lead sponsor of 94 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • older than 18 years-old
  • Spanish speaking
  • having used psychoactive substances to facilitate, maintain and/or improve sexual relations in the last year
  • significant score on the HBI Inventory (of 53 or more)
  • clinically significant discomfort related to sexual practices
  • degree of interference in his/her life of sexual practices greater than or equal to 5 out of 10
  • desire to improve/reduce excessive sexual behaviour

Exclusion criteria

Exclusion Criteria:

  • receiving psychological or psychopharmacological treatment
  • intellectual disability
  • substance dependence (use not associated with sex)
  • personality disorder or other serious or chronic mental disorder diagnosed
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    ACT group

    8 individual weekly sessions including ACT methods

    Behavioral: Acceptance and Commitment Therapy (ACT)

Interventions

  • BehavioralAcceptance and Commitment Therapy (ACT)

    Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.

06

What researchers measure

Primary outcomes

  1. Change in Hypersexual Behavior Inventory (HBI)

    The Hypersexual Behavior Inventory is a 19-item, seven-point Likert-type scale. Scores range between 19 and 95. Higher scores indicate higher levels of Hypersexuality and worse outcome. The presence of a problem of hypersexuality is considered when the score is equal or higher than 53.

    Time frame: Change from Baseline Hypersexuality at 5 months

Secondary outcomes

  1. Change in Drug Abuse Screening Test (Dast-10)

    Drug Abuse Screening Test is a self-administered 10-item questionnaire with dichotomous (Yes/No) responses designed to identify individuals with problematic drug use. Scores range between 0 and 10. Different cutoff points are established regarding problematic substance use, as follows: 0 = low risk or abstinence, 1-2 = risk, 3-5 = harmful, \> 6 = substance dependence. The presence of a problem of substance abuse is considered when the score is equal or higher than 3.

    Time frame: Change from Baseline Drug Abuse at 5 months

  2. Change in Brief Symptom Inventory (BSI)

    Anxiety and Depression subscales of The Brief Symptom Inventory (BSI) include 15 items, each item is rated on a 5-point scale (0 to 4) according to manifestations of anxiety and depression symptoms in the last 30 days (ranging from ''not at-all'' to ''extremely''). Higher scores indicate higher levels of anxiety and depression and worse outcome.

    Time frame: Change from Baseline Anxiety and Depression at 5 months

  3. Change in Acceptance and Action Questionnaire (AAQ-II)

    Acceptance and Action Questionnaire assesses psychological inflexibility. It is a 7-item, seven-point Likert-type scale. Scores range between 7 and 49. Higher scores indicate higher levels of psychological inflexibility and worse outcome. The presence of a problem of psychological inflexibility is considered when the score is equal or higher than 27.

    Time frame: Change from Baseline psychological inflexibility at 5 months

  4. Change in Short Internalized Homonegativity Scale (SIHS)

    Internalized homophobia has been defined as "the internalization of society's homophobic attitudes within a lesbian, gay, or bisexual individual". The Short Internalized Homonegativity Scale measures this phenomenon through a 13-item, five-point Likert-type scale ranging from strongly disagree to strongly agree. Scores range between 13 and 65. Higher scores indicate higher levels of internalized homonegativity and worse outcome. For men, the mean total score is 28.16 (SD = 8.23). The questionnaire includes three sub-scales: public identification as homosexual, sexual comfort with homosexual and social comfort with homosexual people.

    Time frame: Change from Baseline Internalized Homonegativity at 5 months

  5. Change in Social and Emotional Loneliness in Adults (SESLA)

    The Scale of Evaluation of Social and Emotional Loneliness in Adults evaluates loneliness. The scale is comprised of 3 factors: social loneliness, which reflects the lack of friends and social relationships, family loneliness, which reflects the lack of a supportive family environment for the person, and romantic loneliness, which reflects the lack of an intimate romantic relationship. The scale consists of 15 items with which agreement or disagreement is shown according to a 7-point Likert-type scale. Scores range between 15 and 105. Higher scores indicate higher levels of loneliness and worse outcome.

    Time frame: Change from Baseline Emotional Loneliness at 5 months

  6. Change in Awareness, Courage and Responsiveness Scale (ACRS)

    The Awareness, Courage and Responsiveness Scale is the first measure created to assess a contextual-behavioral model of Intimacy, rooted in the Functional Analytic Psychotherapy. It is a 24-item self-report assessment to evaluate the components of the ACR model, using a 7-point Likert-type scale from 1 (never true) to 7 (always true). The scale is comprised of 4 subscales: Others-Awareness (OA), 5 items; Self-Awareness (SA), 6 items; Courage (C), 6 items; and Responsiveness (R), 7 items. The total sum of the items of the scale is considered a global measure of Intimacy (ACRS-T). Scores range between 24 and 168. Higher scores indicate higher levels of skills to generate intimacy and better outcome.

    Time frame: Change from Baseline Awareness, Courage and Responsiveness at 5 months

  7. Change in The Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT)

    The Comprehensive Assessment of Acceptance and Commitment Therapy Processes Change is a 23-item, seven-point Likert-type scale. Scores range between 0 and 138. Higher scores indicate higher levels of psychological flexibility and better outcome. This scale provides more accurate information about each of the psychological processes underlying psychological flexibility. Specifically, it consists of 3 subscales: openness, awareness, and action.

    Time frame: Change from Baseline psychological flexibility at 5 months

  8. Change in the Life Values Questionnaire (VLQ)

    The Life Values Questionnaire relates to 10 domains of different life values, which include: family, marriage/intimate partner relationships, parenthood, friendship, work, education, leisure, spirituality, citizenship, and physical self-care. Participants are asked to evaluate on a Likert scale from 0 to 10 the degree of importance they give to these values, where 0 is of little importance and 10 is of great importance. Additionally, they are asked to rate the degree of consistency with which they engage in actions committed to these values, ranging from 0 to 10. Scores are obtained for different sub-scales: importance, consistency, and discrepancy. As a global score for the questionnaire, the composite score is obtained by subtracting the consistency score from the importance score. Higher scores in discrepancy indicates lower levels of value consistency living and worse outcome.

    Time frame: Change from Baseline value consistency living at 5 months

  9. Change in Time spent planning or practicing sex per week

    Time spent (hours) planning or practicing sex during last week. Higher number of hours indicate worse outcome.

    Time frame: Through study completion, an average of 5 months

  10. Change in Frequency of chemsex encounters per week

    Self-monitoring: Frequency of practicing chemsex during last week. Higher number of chemsex encounters indicate worse outcome.

    Time frame: Through study completion, an average of 5 months

  11. Change in number of different sexual partners per week

    Self-monitoring: Number of different sexual partners during last week. Higher number of different sexual partners indicate worse outcome.

    Time frame: Through study completion, an average of 5 months

  12. Change in Frequency of substance consumption per week

    Self-monitoring: Frequency of consuming substances during last week. Higher number of substances consumed indicate worse outcome.

    Time frame: Through study completion, an average of 5 months

  13. Change in Frequency of risky sexual practices per week

    Self-monitoring: Frequency of risky sexual practices during the last week. Higher number of risky sexual practices indicate worse outcome.

    Time frame: Through study completion, an average of 5 months

  14. Change in number of new diagnoses of sexually transmitted infections per week

    Self-monitoring: Number of new diagnoses of sexually transmitted infections. Higher number of new diagnoses indicate worse outcome.

    Time frame: Through study completion, an average of 5 months

  15. Change in Intensity of cravings subjective scale

    Global self-assessment of intensity of cravings Visual Analogue Scale-ratings. Scores range from 0 = very low intensity to 10 = very high intensity. Higher scores indicate higher levels of intensity of cravings and worse outcome

    Time frame: Through study completion, an average of 5 months

  16. Change in Interference of cravings subjective scale

    Global self-assessment of interference of cravings Visual Analogue Scale-ratings. Scores range from 0 = very low interference to 10 = very high interference. Higher scores indicate higher levels of interference of cravings and worse outcome.

    Time frame: Through study completion, an average of 5 months

  17. Change in Frequency of value committed actions per week

    Self-monitoring: Frequency of value committed actions in presence of craving during last week. Higher number of value committed actions indicate better outcome.

    Time frame: Through study completion, an average of 5 months

07

Study locations

1 site
  • Universidad Europea de Madrid
    Villaviciosa de Odón, Madrid 28670, Spain
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 4, 2024
  • Informed consent form · Apr 4, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06408545
Lead sponsor
Universidad Europea de Madrid
Collaborators
Apoyo Positivo
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Mar 1, 2024
Primary completion
Sep 30, 2024
Completion
Dec 31, 2024
Last update
Apr 23, 2025

Study contacts

Francisco Montesinos, Ph.D.
principal investigator · Universidad Europea de Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion